Similar articles for PMID: 31984804

Year	Number of Results
2008	1
2014	4
2015	9
2016	14
2017	27
2018	21
2019	26
2020	32
2021	16
2022	3
2024	0

1

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Alkhouri N. Alkhouri N. Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29. Expert Opin Investig Drugs. 2020. PMID: 31984804 No abstract available.

2

Treatment options for nonalcoholic steatohepatitis - a safety evaluation.

Issa D, Wattacheril J, Sanyal AJ. Issa D, et al. Expert Opin Drug Saf. 2017 Aug;16(8):903-913. doi: 10.1080/14740338.2017.1343299. Epub 2017 Jul 6. Expert Opin Drug Saf. 2017. PMID: 28641031 Review.

3

Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).

Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Westerouen Van Meeteren MJ, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):117-123. doi: 10.1080/13543784.2020.1668375. Epub 2019 Sep 25. Expert Opin Investig Drugs. 2020. PMID: 31523999 Review.

4

How effective are nonalcoholic fatty liver disease models for drug discovery?

Hundertmark J, Tacke F. Hundertmark J, et al. Expert Opin Drug Discov. 2020 Nov;15(11):1237-1240. doi: 10.1080/17460441.2020.1776258. Epub 2020 Jun 11. Expert Opin Drug Discov. 2020. PMID: 32524859

5

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.

Lefere S, Devisscher L, Tacke F. Lefere S, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):89-92. doi: 10.1080/13543784.2020.1718106. Epub 2020 Jan 20. Expert Opin Investig Drugs. 2020. PMID: 31952447 No abstract available.

6

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.

Alkhouri N. Alkhouri N. Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3. Expert Opin Investig Drugs. 2020. PMID: 31971024 No abstract available.

7

Novel Pharmacotherapy Options for NASH.

Ratziu V. Ratziu V. Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Epub 2016 Mar 22. Dig Dis Sci. 2016. PMID: 27003143 Review.

8

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.

9

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. Alkhouri N, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):135-141. doi: 10.1080/13543784.2020.1668374. Epub 2019 Sep 19. Expert Opin Investig Drugs. 2020. PMID: 31519114 Free PMC article. Review.

10

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!

Ranjbar G, Mikhailidis DP, Sahebkar A. Ranjbar G, et al. Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28. Metabolism. 2019. PMID: 31672448 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

128 results

Results by year